Validation of Cardiac (123)I-MIBG Scintigraphy in Patients with Parkinson's Disease Who Were Diagnosed with Dopamine PET

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2009 Jul 24

PMID 19626324

Citations 20

Authors

Kenji Ishibashi

Yuko Saito

Shigeo Murayama

Kazutomi Kanemaru

Keiichi Oda

Kiichi Ishiwata

Hidehiro Mizusawa

Kenji Ishii

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate the diagnostic potential of cardiac (123)I-labelled metaiodobenzylguanidine ((123)I-MIBG) scintigraphy in idiopathic Parkinson's disease (PD). The diagnosis was confirmed by positron emission tomography (PET) imaging with (11)C-labelled 2beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane ((11)C-CFT) and (11)C-raclopride (together designated as dopamine PET).

Methods: Cardiac (123)I-MIBG scintigraphy and dopamine PET were performed for 39 parkinsonian patients. To estimate the cardiac (123)I-MIBG uptake, heart to mediastinum (H/M) ratios in early and delayed images were calculated. On the basis of established clinical criteria and our dopamine PET findings, 24 patients were classified into the PD group and 15 into the non-PD (NPD) group.

Results: Both early and delayed images showed that the H/M ratios were significantly lower in the PD group than in the NPD group. When the optimal cut-off levels of the H/M ratio were set at 1.95 and 1.60 in the early and delayed images, respectively, by receiver-operating characteristic analysis, the sensitivity of cardiac (123)I-MIBG scintigraphy for the diagnosis of PD was 79.2 and 70.8% and the specificity was 93.3 and 93.3% in the early and delayed images, respectively. In the Hoehn and Yahr 1 and 2 PD patients, the sensitivity decreased by 69.2 and 53.8% in the early and delayed images, respectively.

Conclusion: In early PD cases, cardiac (123)I-MIBG scintigraphy is of limited value in the diagnosis, because of its relatively lower sensitivity. However, because of its high specificity for the overall cases, cardiac (123)I-MIBG scintigraphy may assist in the diagnosis of PD in a complementary role with the dopaminergic neuroimaging.

Citing Articles

Covering Basic Needs on Molecular Imaging.

Peralta C, Strafella A, Kim H Mov Disord Clin Pract. 2024; 11(1):10-13.

PMID: 38291843 PMC: 10828620. DOI: 10.1002/mdc3.13905.

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review.

Rissardo J, Caprara A Brain Sci. 2023; 13(10).

PMID: 37891838 PMC: 10605004. DOI: 10.3390/brainsci13101471.

High clinical diagnostic accuracy of combined salivary gland and myocardial metaiodobenzylguanidine scintigraphy in the diagnosis of Parkinson's disease.

Li S, Yue L, Chen S, Wu Z, Zhang J, Hong R Front Aging Neurosci. 2023; 14:1066331.

PMID: 36711204 PMC: 9875016. DOI: 10.3389/fnagi.2022.1066331.

High Prevalence of Early Parkinson's Disease in Patients With Subtle Parkinsonian Signs.

Sasaki S Front Neurol. 2021; 12:656679.

PMID: 34305780 PMC: 8299703. DOI: 10.3389/fneur.2021.656679.

Assessment of myocardial sympathetic innervation with F-FDOPA-PET/CT in patients with autonomic dysfunction: Feasibility study in IPD patients.

Woodard P J Nucl Cardiol. 2021; 29(3):1291-1292.

PMID: 33751475 DOI: 10.1007/s12350-021-02572-3.

References

Bokobza B, Ruberg M, Scatton B, Agid Y . [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol. 1984; 99(2-3):167-75. DOI: 10.1016/0014-2999(84)90238-3. View

Rinne J, LAIHINEN A, Rinne U, Nagren K, Bergman J, Ruotsalainen U . PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord. 1993; 8(2):134-8. DOI: 10.1002/mds.870080203. View

Fearnley J, Lees A . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 ( Pt 5):2283-301. DOI: 10.1093/brain/114.5.2283. View

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y . Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005; 76(2):249-51. PMC: 1739515. DOI: 10.1136/jnnp.2004.037028. View

Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H . (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67(2):189-94. PMC: 1736461. DOI: 10.1136/jnnp.67.2.189. View

Antonini A, Leenders K, Reist H, Thomann R, Beer H, LOCHER J . Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol. 1993; 50(5):474-80. DOI: 10.1001/archneur.1993.00540050026010. View

Jankovic J, Rajput A, McDermott M, Perl D . The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000; 57(3):369-72. DOI: 10.1001/archneur.57.3.369. View

Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K . Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999; 40(3):371-5. View

Antonini A, Schwarz J, Oertel W, Pogarell O, Leenders K . Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord. 1997; 12(1):33-8. DOI: 10.1002/mds.870120107. View

10.

Spiegel J, Mollers M, Jost W, Fuss G, Samnick S, Dillmann U . FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 2005; 20(5):552-61. DOI: 10.1002/mds.20369. View

11.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

12.

Guttman M, Seeman P, Reynolds G, Riederer P, Jellinger K, Tourtellotte W . Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol. 1986; 19(5):487-92. DOI: 10.1002/ana.410190510. View

13.

Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T . Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003; 74(4):423-6. PMC: 1738357. DOI: 10.1136/jnnp.74.4.423. View

14.

Taki J, Nakajima K, Hwang E, Matsunari I, Komai K, Yoshita M . Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med. 2000; 27(5):566-73. DOI: 10.1007/s002590050544. View

15.

Kawamura K, Oda K, Ishiwata K . Age-related changes of the [11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET study. Ann Nucl Med. 2003; 17(3):249-53. DOI: 10.1007/BF02990030. View

16.

Kim Y, Ichise M, Ballinger J, Vines D, Erami S, Tatschida T . Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002; 17(2):303-12. DOI: 10.1002/mds.10042. View

17.

Raffel D, Koeppe R, Little R, Wang C, Liu S, Junck L . PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med. 2006; 47(11):1769-77. View

18.

Li S, Dendi R, Holmes C, Goldstein D . Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol. 2002; 52(2):220-3. DOI: 10.1002/ana.10236. View

19.

Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G . Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna). 2004; 112(5):677-92. DOI: 10.1007/s00702-004-0208-x. View

20.

Hashimoto M, Kawasaki K, Suzuki M, Mitani K, Murayama S, Mishina M . Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy. Neuroreport. 2008; 19(2):145-50. DOI: 10.1097/WNR.0b013e3282f3e3d8. View